K
Kurt Lingenhoehl
Researcher at Novartis
Publications - 26
Citations - 2984
Kurt Lingenhoehl is an academic researcher from Novartis. The author has contributed to research in topics: Agonist & GABAB receptor. The author has an hindex of 17, co-authored 26 publications receiving 2857 citations. Previous affiliations of Kurt Lingenhoehl include Ciba Specialty Chemicals.
Papers
More filters
Journal ArticleDOI
Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity
Lidong Liu,Tak Pan Wong,Mario F. Pozza,Kurt Lingenhoehl,Yushan Wang,Morgan Sheng,Yves Auberson,Yu Tian Wang +7 more
TL;DR: Using hippocampal slice preparations, it is shown that selectively blocking NMDARs that contain the NR2B subunit abolishes the induction of LTD but not LTP, demonstrating that distinct N MDAR subunits are critical factors that determine the polarity of synaptic plasticity.
Journal ArticleDOI
Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.
Stephan Urwyler,Johannes Mosbacher,Kurt Lingenhoehl,Jakob Heid,Karin Hofstetter,Wolfgang Froestl,Bernhard Bettler,Klemens Kaupmann +7 more
TL;DR: It is shown that CGP7930 enhances the inhibitory effect of L-baclofen on the oscillatory activity of cultured cortical neurons and may represent a novel means of therapeutic interference with the GABA-ergic system.
Journal ArticleDOI
5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.
TL;DR: NMDA antagonists derived from 5-phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione (3a) are potent anticonvulsant agents, and display strong protective effects in the electroshock-induced convulsion assay in mice.
Journal ArticleDOI
Behavioral Characterization of the Novel GABAB Receptor-Positive Modulator GS39783 (N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-Like Activity without Side Effects Associated with Baclofen or Benzodiazepines
John F. Cryan,Peter H. Kelly,Frederique Chaperon,Conrad Gentsch,Cedric Mombereau,Kurt Lingenhoehl,Wolfgang Froestl,Bernhard Bettler,Klemens Kaupmann,Will Spooren +9 more
TL;DR: The data obtained here suggest that positive modulation of GABAB receptors may serve as a novel therapeutic strategy for the development of anxiolytics, with a superior side effect profile to both baclofen and benzodiazepines.
Journal ArticleDOI
γ-Hydroxybutyrate is a weak agonist at recombinant GABAB receptors
Kurt Lingenhoehl,Richard Brom,Jakob Heid,Pascal Beck,Wolfgang Froestl,Klemens Kaupmann,Bernhard Bettler,Johannes Mosbacher +7 more
TL;DR: Results indicate that GHB is a weak partial agonist at the GABA binding site of GABA(B)R1/R2, and this hypothesis is consistent with previous reports on GHB and gamma-aminobutyric acid.